MCID: ELP001
MIFTS: 43

Elephantiasis

Categories: Immune diseases, Infectious diseases, Mental diseases

Aliases & Classifications for Elephantiasis

MalaCards integrated aliases for Elephantiasis:

Name: Elephantiasis 12 73 54 3 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4976
MeSH 44 D004604
NCIt 50 C34569
SNOMED-CT 67 155485008
UMLS 70 C0013882

Summaries for Elephantiasis

CDC : 3 Lymphatic filariasis, considered globally as a neglected tropical disease (NTD), is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes. People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

MalaCards based summary : Elephantiasis is related to podoconiosis and filarial elephantiasis. An important gene associated with Elephantiasis is NF1 (Neurofibromin 1), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Petrolatum and Glycerol have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and lymph node, and related phenotype is digestive/alimentary.

Wikipedia : 73 Elephantiasis is the enlargement and hardening of limbs or body parts due to tissue swelling. It is... more...

Related Diseases for Elephantiasis

Diseases related to Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 417)
# Related Disease Score Top Affiliating Genes
1 podoconiosis 32.3 TVP23C HLA-DQA2 CDRT4
2 filarial elephantiasis 31.4 VEGFC IL5 IL4 IL13 IL10 GPT2
3 filariasis 30.9 IL5 IL10 FLT4
4 loiasis 30.7 IL5 IL4 IL13 IL10 GPT2 CD4
5 chlamydia 30.2 IL5 IL4 IL10
6 lymphangitis 30.1 VEGFC GPT2 FLT4 CD4
7 congenital lymphedema 30.1 VEGFC FLT4
8 leishmaniasis 30.0 IL5 IL4 IL13 IL10
9 cellulitis 30.0 RNASE3 IL5 FLT4 CD4
10 onchocerciasis 30.0 RNASE3 IL5 IL4 IL13 ELANE
11 primary lymphedema 30.0 VEGFC FLT4
12 actinomycosis 29.9 IL4 IL10 CD4
13 basidiobolomycosis 29.9 IL4 IL10
14 tertiary syphilis 29.8 IL10 CD4
15 leprosy 3 29.8 IL5 IL4 IL13 IL10 CD4
16 peritonitis 29.7 IL4 IL10 ELANE
17 lymphatic malformation 1 29.7 VEGFC FLT4
18 inguinal hernia 29.7 NF1 IL13 ELN ELANE
19 systemic scleroderma 29.5 IL4 IL13 IL10 ELN CD4
20 cutaneous leishmaniasis 29.5 IL5 IL4 IL13 IL10
21 contact dermatitis 29.5 IL5 IL4 IL10 CD4
22 tetanus 29.5 IL5 IL4 IL13 IL10
23 bone inflammation disease 29.3 IL4 IL13 IL10 CD4
24 crohn's disease 29.3 IL4 IL13 IL10 CD4
25 dermatitis 29.2 RNASE3 IL5 IL4 IL13 IL10 CD4
26 fungal infectious disease 29.1 IL5 IL4 IL13 IL10 CD4
27 respiratory failure 29.0 RNASE3 IL5 IL13 IL10 ELANE CD4
28 skin disease 29.0 RNASE3 IL5 IL4 IL13 IL10 ELN
29 parasitic helminthiasis infectious disease 29.0 RNASE3 IL5 IL4 IL13 IL10 CD4
30 psoriasis 28.9 IL5 IL4 IL13 IL10 ELANE CD4
31 malaria 28.7 RNASE3 IL5 IL4 IL13 IL10 ELANE
32 eye disease 28.7 IL5 IL4 IL13 IL10 FLT4 CD4
33 pulmonary disease, chronic obstructive 28.6 RNASE3 IL5 IL4 IL13 IL10 ELN
34 hereditary lymphedema i 10.7
35 neurofibromatosis 10.4
36 mid-dermal elastolysis 10.4 ELN ELANE
37 cerebral aneurysms 10.4 ELN ELANE
38 erysipelas 10.4
39 mechanical ectropion 10.3 NFIC NF1
40 loeffler endocarditis 10.3 RNASE3 IL5
41 tropical endomyocardial fibrosis 10.3 IL4 IL10
42 childhood-onset asthma 10.3 RNASE3 IL13
43 acute gonococcal cervicitis 10.3 IL4 IL10
44 cytokine deficiency 10.3 IL5 IL13
45 exercise-induced bronchoconstriction 10.3 RNASE3 IL13
46 aztreonam allergy 10.3 IL5 IL13
47 autoimmune hepatitis type 1 10.3 IL4 IL10
48 patulous eustachian tube 10.3 RNASE3 IL5 ELN
49 cefaclor allergy 10.3 IL5 IL13
50 toxic oil syndrome 10.2 IL5 IL4

Graphical network of the top 20 diseases related to Elephantiasis:



Diseases related to Elephantiasis

Symptoms & Phenotypes for Elephantiasis

MGI Mouse Phenotypes related to Elephantiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 CD4 FLT4 IL10 IL13 IL4 IL5

Drugs & Therapeutics for Elephantiasis

Drugs for Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Petrolatum Approved, Investigational Phase 3 8009-03-8
2
Glycerol Approved, Investigational Phase 3 56-81-5 753
3
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
4
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
5
Sodium citrate Approved, Investigational Phase 3 68-04-2
6
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
7 Protective Agents Phase 3
8 Sodium hypochlorite Phase 3
9 Eusol Phase 3
10 Antimalarials Phase 3
11 Milbemycin Phase 3
12 Citrate Phase 3
13
Piperazine Approved, Vet_approved 110-85-0 4837
14
Mebendazole Approved, Vet_approved 31431-39-7 4030
15
Permethrin Approved, Investigational 52645-53-1 40326
16 Anticoagulants
17 Chelating Agents
18 DMP 777 157341-41-8
19 Piperazine citrate
20 Calcium, Dietary
21 Liver Extracts
22
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
4 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
5 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
6 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
7 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929134 Phase 3 Doxycycline;Placebo
8 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02927496 Phase 3 Doxycycline;Placebo
9 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
10 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
11 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Enrolling by invitation NCT04410406 Phase 3 Ivermectin;Diethylcarbamazine;Albendazole;Moxidectin
12 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
13 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
14 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
15 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
16 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
17 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
18 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
19 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
20 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
21 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
22 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
23 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
24 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
25 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
26 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
27 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
28 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
29 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
30 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
31 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
32 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
33 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
34 Exhaled NO Testing in Filariasis Completed NCT01628497
35 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
36 Research for Elimination of Human Filariasis Completed NCT00145223
37 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
38 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Active, not recruiting NCT04258670
39 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Enrolling by invitation NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
40 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;Albendazole 400mg and ivermectin 200mcg/kg;albendazole 800mg and ivermectin 400mcg/kg bi-annually
41 Investigation of the Pathogenesis of Podoconiosis Using RNA-seq and Immunopathologic Approaches Terminated NCT01939431

Search NIH Clinical Center for Elephantiasis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ivermectin

Genetic Tests for Elephantiasis

Anatomical Context for Elephantiasis

MalaCards organs/tissues related to Elephantiasis:

40
Skin, Lung, Lymph Node, Heart, Bone Marrow, T Cells, Eye

Publications for Elephantiasis

Articles related to Elephantiasis:

(show top 50) (show all 1505)
# Title Authors PMID Year
1
Circulating fibrosis markers, eosinophil cationic protein and eosinophil protein X in patients with Wuchereria bancrofti infection: association with clinical status. 54 61
16800126 2006
2
[Physiopathology of vulvar elephantiasis of filarial origin. A case report]. 61
33726892 2021
3
A review on the interactions between dendritic cells, filarial parasite and parasite-derived molecules in regulating the host immune responses. 61
33247468 2021
4
A late diagnosis of hyperhomocysteinemia with probable evolution to verrucous elephantiasis nostra and leg ulcers. 61
33581929 2021
5
A Case of Elephantiasis Nostras Verrucosa Secondary to Lymphedema Praecox Complicated by Congestive Cardiac Failure. 61
33714971 2021
6
Successful surgical resection and reconstruction of scrotal elephantiasis. 61
33718810 2021
7
The Eagle effect in the Wolbachia-worm symbiosis. 61
33627171 2021
8
Historical account of endocrinal disorders in Unani medicine. 61
33550777 2021
9
Improved Psychosocial Status after Surgery for Genital Elephantiasis due to Hidradenitis Suppurativa: A Prospective Study of a Case Series. 61
33470416 2021
10
Weeping wounds and sepsis: a complication of elephantiasis nostras verrucosa. 61
33495168 2021
11
Ivermectin, a potential anticancer drug derived from an antiparasitic drug. 61
32971268 2021
12
Dual RNAseq analyses at soma and germline levels reveal evolutionary innovations in the elephantiasis-agent Brugia malayi, and adaptation of its Wolbachia endosymbionts. 61
33406151 2021
13
Scrotal Lymphangiectasia with Penile Elephantiasis in Underlying Lymphatic Filariasis-Challenging the Diagnostic Mind! A Case Report. 61
33401419 2021
14
Elimination of Lymphatic Filariasis in Shandong Province, China, 1957-2015. 61
32795160 2020
15
Biodiversity of mosquitoes and Mansonia uniformis as a potential vector of Wuchereria bancrofti in Hulu Sungai Utara District, South Kalimantan, Indonesia. 61
33488003 2020
16
The story of Lymphatic Filariasis elimination as a public health problem from Yemen. 61
32828916 2020
17
Elephantiasis in a patient with thyroid eye disease. 61
33349089 2020
18
A rare presentation of elephantiasis involving vulvae in an Indian female. 61
32525103 2020
19
Urological infections in the developing world: an increasing problem in developed countries. 61
32108257 2020
20
A case of elephantiasis nostras verrucosa treated successfully by a new type of compressive garment. 61
32981199 2020
21
Unravelling the Biological Activities of the Byttneria pilosa Leaves Using Experimental and Computational Approaches. 61
33076534 2020
22
Pancytopenia: a rare cause for a common presentation. 61
32539585 2020
23
Shaving Technique and Compression Therapy for Elephantiasis Nostras Verrucosa (Lymphostatic Verrucosis) of Forefeet and Toes in End-Stage Primary Lymphedema: A 5 Year Follow-Up Study in 28 Patients and a Review of the Literature. 61
32998425 2020
24
Concomitance of Elephantiasis Nostras Verrucosa and Systemic Sclerosis. 61
32804751 2020
25
Adapting techniques for calcium imaging in muscles of adult Brugia malayi. 61
32803437 2020
26
[Elephantiasis nostras verrucosa]. 61
32651150 2020
27
[Status of chronic filariasis: a cross-sectional study in Jiangxi Province, 2018]. 61
33660481 2020
28
Nearly Complete Genome Sequence of Brugia malayi Strain FR3. 61
32527783 2020
29
Is vitiligo associated with wearing plastic shoes in a podoconiosis endemic region of Ethiopia? 61
32614792 2020
30
Hybrid Treatment Combining Lymphaticovenous Anastomoses and the Oriental Herbal Medicine Bofutsushosan for Obesity-Associated Lower Leg Elephantiasis Nostras Verrucosa: A Case Report. 61
32519905 2020
31
Visual Dermatology: Elephantiasis Nostras Verrucosa. 61
32442017 2020
32
Elephantiasis nostras verrucosa: a severe complication of lymphoedema. 61
32468952 2020
33
Disease Specific to Chronic Lymphedema and Class III Obesity. 61
32351576 2020
34
Microfilariae in bone marrow aspirate of a case of myelofibrosis: A cause or coincidence? 61
32362629 2020
35
Diagnosis of elephantiasis nostras verrucosa as a clinical mani-festation of Kaposi's sarcoma. 61
31999679 2020
36
The Effect of Lymphoedema Exercises and Foot Elevation on the Quality of Life of Patients with Elephantiasis. 61
32547621 2020
37
Magnitude of Podoconiosis and Its Associated Factors among an Adult Population in Waghmra Zone, Ethiopia: A Cross-Sectional Study. 61
32832556 2020
38
A Study on Serological Reactivity Profile of Different Antigen Preparations with Bancroftian filariasis Human Infection Sera. 61
32096736 2020
39
An Insight into the Discovery of Potent Antifilarial Leads Against Lymphatic Filariasis. 61
31800381 2020
40
Lymphatic filariasis presenting as retroperitoneal cyst. 61
32775296 2020
41
Mapping the global distribution of podoconiosis: Applying an evidence consensus approach. 61
31790408 2019
42
Elephantiasis nostras verrucosa: an atypical presentation following intrapelvic lymphoma. 61
32045164 2019
43
Treatment of Elephantiasis Nostras Verrucosa with CO2 Laser. 61
31807453 2019
44
Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. 61
31400299 2019
45
[Current status of chronic filariasis in Huai'an City]. 61
32064819 2019
46
Elephantiasis nostras verrucosa in the setting of lymphoedema tarda and neurofibromatosis type 1. 61
31712230 2019
47
Tolvaptan for the Treatment of Elephantiasis Nostras Verrucosa. 61
31327824 2019
48
Elephantiasis and the Origins of Chronic Bowel Damage in Crohn's Disease. 61
31100451 2019
49
Sonographic Detection of Cutaneous Myiasis. 61
31763611 2019
50
Rare association of microfilaria with poorly differentiated mucin-secreting metastatic carcinoma in liver aspirate cytology. 61
31645405 2019

Variations for Elephantiasis

Expression for Elephantiasis

Search GEO for disease gene expression data for Elephantiasis.

Pathways for Elephantiasis

Pathways related to Elephantiasis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 VEGFC NF1 IL5 IL4 IL13 IL10
2
Show member pathways
13.29 VEGFC IL5 IL4 IL13 IL10 FLT4
3
Show member pathways
13.24 NF1 IL5 IL4 IL13 IL10 HLA-DQA2
4
Show member pathways
13.16 VEGFC IL5 IL4 IL13 IL10 FLT4
5 12.73 VEGFC IL5 IL4 IL13 FLT4
6
Show member pathways
12.61 RNASE3 IL5 IL4 IL13 IL10 HLA-DQA2
7
Show member pathways
12.47 IL5 IL4 IL13 IL10 HLA-DQA2 CD4
8
Show member pathways
12.29 IL5 IL4 IL13 IL10
9
Show member pathways
12.09 VEGFC IL5 IL4 IL13 IL10 FLT4
10 11.88 IL5 IL4 IL10 CD4
11 11.86 IL4 IL13 IL10
12 11.79 IL5 IL4 HLA-DQA2 CD4
13 11.7 IL5 IL4 IL13
14 11.58 IL5 IL4 IL13 ELN
15 11.57 IL5 IL4 IL10
16 11.54 IL5 IL4 IL10
17 11.46 IL5 IL4 IL13 IL10 CD4
18 11.4 IL4 IL13 IL10
19 11.21 IL5 IL4 IL13
20 11.02 IL5 IL4 IL13 IL10 CD4
21 10.97 IL5 IL4 IL13 IL10
22
Show member pathways
10.82 VEGFC FLT4
23 10.82 VEGFC IL5 IL4 IL13 IL10 FLT4
24 10.69 IL5 IL4 IL13
25 10.48 IL5 IL4 IL13 IL10 CD4

GO Terms for Elephantiasis

Cellular components related to Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 VEGFC RNASE3 IL5 IL4 IL13 IL10

Biological processes related to Elephantiasis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of endothelial cell proliferation GO:0001938 9.65 VEGFC IL10 FLT4
2 positive regulation of B cell proliferation GO:0030890 9.61 IL5 IL4 IL13
3 negative regulation of endothelial cell apoptotic process GO:2000352 9.58 IL4 IL13 IL10
4 negative regulation of inflammatory response GO:0050728 9.56 IL4 IL13 IL10 ELANE
5 cytokine-mediated signaling pathway GO:0019221 9.55 IL5 IL4 IL13 IL10 CD4
6 vascular endothelial growth factor signaling pathway GO:0038084 9.54 VEGFC FLT4
7 macrophage activation GO:0042116 9.52 IL4 IL13
8 positive regulation of MHC class II biosynthetic process GO:0045348 9.51 IL4 IL10
9 positive regulation of mast cell degranulation GO:0043306 9.49 IL4 IL13
10 type 2 immune response GO:0042092 9.46 IL4 IL10
11 immune response GO:0006955 9.43 IL5 IL4 IL13 IL10 HLA-DQA2 CD4
12 negative regulation of complement-dependent cytotoxicity GO:1903660 9.37 IL4 IL13
13 regulation of isotype switching GO:0045191 9.32 IL4 IL10
14 positive regulation of immunoglobulin production GO:0002639 8.8 IL5 IL13 IL10

Molecular functions related to Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL5 IL4 IL13 IL10
2 growth factor activity GO:0008083 8.92 VEGFC IL5 IL4 IL10

Sources for Elephantiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....